BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Equecabtagene autoleucel readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Equecabtagene autoleucel\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04561557-3255@assetmemo.bio
DTSTAMP:20261121T010122Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:Equecabtagene autoleucel: Phase 1 readout est. (NCT04561557)
DESCRIPTION:Equecabtagene autoleucel\, phase 1.\nStudy: Safety and Efficacy
  of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory 
 Diseases of the Nervous System\nEstimated primary completion: 22 February 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/equecabtagene-a
 utoleucel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04561557
URL:https://assetmemo.bio/drug/equecabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06464991-3255@assetmemo.bio
DTSTAMP:20261121T010122Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Equecabtagene autoleucel: Phase 3 readout est. (NCT06464991)
DESCRIPTION:Equecabtagene autoleucel\, phase 3\, Multiple Myeloma.\nStudy: 
 A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANB
 A-03)\nEstimated primary completion: August 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/equecabtagene-autoleucel#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06464991
URL:https://assetmemo.bio/drug/equecabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06902844-3255@assetmemo.bio
DTSTAMP:20261121T010122Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Equecabtagene autoleucel: Phase na readout est. (NCT06902844)
DESCRIPTION:Equecabtagene autoleucel\, phase na.\nStudy: Equecabtagene Auto
 leucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythem
 atosus (SLE)\nEstimated primary completion: 31 October 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/equecabtagene-autoleucel#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06902844
URL:https://assetmemo.bio/drug/equecabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07752264-3255@assetmemo.bio
DTSTAMP:20261121T010122Z
DTSTART;VALUE=DATE:20300815
DTEND;VALUE=DATE:20300816
SUMMARY:Equecabtagene autoleucel: Phase 1/2 readout est. (NCT07752264)
DESCRIPTION:Equecabtagene autoleucel\, phase 1/2.\nStudy: A Phase I/II Stud
 y of Eque-cel in Subjects Withimmune-mediated Necrotizing Myopathy\nEstima
 ted primary completion: 15 August 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/equecabtagene-autoleucel#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07752264
URL:https://assetmemo.bio/drug/equecabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
